Group 1 - Morgan Stanley believes that the stock price of Chinese traditional medicine will decline in the next 30 days, with a probability estimated between 70% to 80% [1] - The rating is set to "Underweight" with a target price of HKD 1.5 [1] - The expected stock price movement is attributed to a profit warning, as the company anticipates a loss for the fiscal year 2025, marking the first occurrence since 2013 [1] Group 2 - The company is facing challenges due to a shrinking market size, and it has not disclosed specific plans for market expansion through internal resources or acquisitions [1] - As a result, market visibility regarding the company's performance in 2026 is low, leading to expectations of further downside potential for the stock price [1]
大行评级｜大摩：预计中国中药股价将在未来30天下跌，目标价1.5港元